Literature DB >> 21922347

85% of maximal age-predicted heart rate is not a valid endpoint for exercise treadmill testing.

Mohit Jain1, Chileshe Nkonde, Ben A Lin, Alerice Walker, Frans J Th Wackers.   

Abstract

BACKGROUND: Exercise testing should be symptom-limited. Nevertheless, 40% of clinical laboratories applying for ICANL accreditation use 85% of maximal age-predicted heart rate (MPHR) as the primary exercise endpoint. We hypothesized that this approach importantly may underestimate exercise capacity and inducible ischemia.
METHODS: Two patient cohorts were studied. 1. A prospective registry of patients referred for exercise testing. 2. A retrospective cohort of patients with positive exercise ECG.
RESULTS: Of 306 registry patients, 211 (69%) continued exercising after reaching 85% MPHR to maximal HR of 101% ± 7% of MPHR. Forty-two patients (14%) stopped <1 minute after achieving 85% MPHR; 53 (17%) did not achieve 85% MPHR. More women (75%) than men (64%) achieved >85% MPHR (P = .02). Of 300 patients with positive ECG, 232 patients (77%) exercised to >85% MPHR. At 85% MPHR 144 patients (62%) had positive ECG (1.2 ± .7 mm ST depression) compared to 232 patients (100%) at peak exercise (2.3 ± .9 mm ST depression, P < .001). Mean workload at 85% MPHR was 7.3 ± 2.4 METs compared to 10.6 ± 2.8 METs at peak exercise (P < .001).
CONCLUSION: Achievement of 85% MPHR is not a valid diagnostic or functional exercise endpoint because it significantly underestimates exercise capacity and inducible ischemia.

Entities:  

Mesh:

Year:  2011        PMID: 21922347     DOI: 10.1007/s12350-011-9454-0

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  20 in total

1.  ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines).

Authors:  Raymond J Gibbons; Gary J Balady; J Timothy Bricker; Bernard R Chaitman; Gerald F Fletcher; Victor F Froelicher; Daniel B Mark; Ben D McCallister; Aryan N Mooss; Michael G O'Reilly; William L Winters; Raymond J Gibbons; Elliott M Antman; Joseph S Alpert; David P Faxon; Valentin Fuster; Gabriel Gregoratos; Loren F Hiratzka; Alice K Jacobs; Richard O Russell; Sidney C Smith
Journal:  J Am Coll Cardiol       Date:  2002-10-16       Impact factor: 24.094

2.  EXERCISING TESTING IN ADULT NORMAL SUBJECTS AND CARDIAC PATIENTS.

Authors:  R A BRUCE; J R BLACKMON; J W JONES; G STRAIT
Journal:  Pediatrics       Date:  1963-10       Impact factor: 7.124

3.  Quantifying exertion level during exercise stress testing using percentage of age-predicted maximal heart rate, rate pressure product, and perceived exertion.

Authors:  Sherry Pinkstaff; Mary Ann Peberdy; Michael C Kontos; Sheryl Finucane; Ross Arena
Journal:  Mayo Clin Proc       Date:  2010-12       Impact factor: 7.616

Review 4.  Physical activity and the prevention of coronary heart disease.

Authors:  S M Fox; J P Naughton; W L Haskell
Journal:  Ann Clin Res       Date:  1971-12

5.  Exercise capacity and the risk of death in women: the St James Women Take Heart Project.

Authors:  Martha Gulati; Dilip K Pandey; Morton F Arnsdorf; Diane S Lauderdale; Ronald A Thisted; Roxanne H Wicklund; Arfan J Al-Hani; Henry R Black
Journal:  Circulation       Date:  2003-09-15       Impact factor: 29.690

6.  Influence of exercise intensity on the presence, distribution, and size of thallium-201 defects.

Authors:  G V Heller; I Ahmed; P L Tilkemeier; M M Barbour; C E Garber
Journal:  Am Heart J       Date:  1992-04       Impact factor: 4.749

7.  The electrocardiographic exercise test in a population with reduced workup bias: diagnostic performance, computerized interpretation, and multivariable prediction. Veterans Affairs Cooperative Study in Health Services #016 (QUEXTA) Study Group. Quantitative Exercise Testing and Angiography.

Authors:  V F Froelicher; K G Lehmann; R Thomas; S Goldman; D Morrison; R Edson; P Lavori; J Myers; C Dennis; R Shabetai; D Do; J Froning
Journal:  Ann Intern Med       Date:  1998-06-15       Impact factor: 25.391

Review 8.  The prognostic value of exercise capacity: a review of the literature.

Authors:  C K Morris; K Ueshima; T Kawaguchi; A Hideg; V F Froelicher
Journal:  Am Heart J       Date:  1991-11       Impact factor: 4.749

9.  Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study.

Authors:  Samia Mora; Rita F Redberg; Yadong Cui; Maura K Whiteman; Jodi A Flaws; A Richey Sharrett; Roger S Blumenthal
Journal:  JAMA       Date:  2003-09-24       Impact factor: 56.272

10.  Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease.

Authors:  D B Mark; L Shaw; F E Harrell; M A Hlatky; K L Lee; J R Bengtson; C B McCants; R M Califf; D B Pryor
Journal:  N Engl J Med       Date:  1991-09-19       Impact factor: 91.245

View more
  11 in total

1.  Another conclusion on "85% of maximal age-predicted heart rate is not a valid endpoint for exercise treadmill testing".

Authors:  Ali Gholamrezanezhad; Sahar Mirpour; Behnam S Jazayeri-Moghadass
Journal:  J Nucl Cardiol       Date:  2012-06       Impact factor: 5.952

2.  ⁸²Rb PET myocardial perfusion imaging is superior to ⁹⁹mTc-labelled agent SPECT in patients with known or suspected coronary artery disease.

Authors:  Albert Flotats; Paco E Bravo; Kenji Fukushima; Muhammad A Chaudhry; Jennifer Merrill; Frank M Bengel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-05-31       Impact factor: 9.236

3.  Is downstream cardiac testing required in patients with reduced functional capacity and otherwise negative exercise stress test? A single center observational study.

Authors:  Mark Whitman; Surendran Sabapathy; Carly Jenkins; Lewis Adams
Journal:  Cardiol J       Date:  2018-09-20       Impact factor: 2.737

4.  Revisiting age-predicted maximal heart rate: Can it be used as a valid measure of effort?

Authors:  Ross Arena; Jonathan Myers; Leonard A Kaminsky
Journal:  Am Heart J       Date:  2015-12-17       Impact factor: 4.749

5.  ST-segment changes with exercise stress.

Authors:  Yoke Ching Lim; Swee-Guan Teo; Kian-Keong Poh
Journal:  Singapore Med J       Date:  2016-07       Impact factor: 1.858

6.  Safety and feasibility of adjunctive regadenoson injection at peak exercise during exercise myocardial perfusion imaging: The Both Exercise and Regadenoson Stress Test (BERST) trial.

Authors:  M I Ross; E Wu; J T Wilkins; D Gupta; S Shen; D Aulwes; K Montero; T A Holly
Journal:  J Nucl Cardiol       Date:  2013-02-13       Impact factor: 5.952

7.  The prognostic significance of heart rate recovery is not dependent upon maximal effort in patients with heart failure.

Authors:  Lawrence P Cahalin; Daniel E Forman; Paul Chase; Marco Guazzi; Jonathan Myers; Daniel Bensimhon; Mary Ann Peberdy; Euan Ashley; Erin West; Ross Arena
Journal:  Int J Cardiol       Date:  2013-02-04       Impact factor: 4.164

8.  Measured maximal heart rates compared to commonly used age-based prediction equations in the Heritage Family Study.

Authors:  M A Sarzynski; T Rankinen; C P Earnest; A S Leon; D C Rao; J S Skinner; C Bouchard
Journal:  Am J Hum Biol       Date:  2013-08-01       Impact factor: 1.937

9.  Safety and feasibility of regadenoson use for suboptimal heart rate response during symptom-limited standard Bruce exercise stress test.

Authors:  Sara L Partington; Viswanatha Lanka; Jon Hainer; Ron Blankstein; Hicham Skali; Daniel E Forman; Marcelo F Di Carli; Sharmila Dorbala
Journal:  J Nucl Cardiol       Date:  2012-05-08       Impact factor: 5.952

10.  EACPR/AHA Scientific Statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations.

Authors:  Marco Guazzi; Volker Adams; Viviane Conraads; Martin Halle; Alessandro Mezzani; Luc Vanhees; Ross Arena; Gerald F Fletcher; Daniel E Forman; Dalane W Kitzman; Carl J Lavie; Jonathan Myers
Journal:  Circulation       Date:  2012-09-05       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.